Last reviewed · How we verify
AK127
At a glance
| Generic name | AK127 |
|---|---|
| Also known as | Subjects will receive AK127 by intravenous administration |
| Sponsor | Akeso |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (EARLY_PHASE1)
- A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors (PHASE1)
- A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK127 CI brief — competitive landscape report
- AK127 updates RSS · CI watch RSS
- Akeso portfolio CI